Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.
- First patient treated in Phase 1 HARNESS-1 lung cancer trial
- RC220 dose escalated to 80mg/m² in CPACS trial with no safety concerns
- Preclinical data confirms RC220 silences c-MYC oncogene
- Raised $18 million in the quarter, cash runway into 2028
- New institutional investor and strengthened corporate operations
Clinical Milestones Mark Progress for RC220
Racura Oncology (ASX:RAC) has marked a transformative quarter with the first patient dosed in its Phase 1 HARNESS-1 trial, testing RC220 in combination with osimertinib for EGFR-mutated non-small cell lung cancer (NSCLC). This milestone, achieved at Monash Health in Victoria, is a critical step in evaluating the drug’s efficacy in a patient population with significant unmet medical needs.
Meanwhile, the Phase 1 Cardioprotection and Anticancer Synergy (CPACS) trial has cleared a safety review to escalate RC220 dosing to 80mg/m². The absence of dose-limiting toxicities in earlier cohorts reinforces RC220’s tolerability and supports continued dose escalation across sites in Australia, Hong Kong, and South Korea.
Preclinical Data Highlights c-MYC Silencing Mechanism
At the 2026 American Association for Cancer Research (AACR) Annual Meeting, Racura presented compelling preclinical evidence that (E,E)-bisantrene, the active compound in RC220, effectively silences the c-MYC oncogene by stabilising G-quadruplex DNA structures in its promoter region. Given c-MYC’s dysregulation in up to 70% of cancers, this mechanism underpins Racura’s multi-indication clinical strategy targeting MYC-driven tumours.
Robust Fundraising Secures Runway Into 2028
Financially, Racura closed the quarter with $34.3 million in cash and equivalents, bolstered by $18 million raised through exercised options, private placements, and a no-fee underwriting agreement. The capital raise included a $1 million strategic placement to a specialist institutional investor, diversifying the shareholder base and signalling growing confidence in Racura’s clinical programs.
This cash position is sufficient to fund all committed activities into calendar year 2028, providing a clear runway for the company to advance its Phase 3 EMILI trial in acute myeloid leukaemia (AML), alongside the ongoing Phase 1 studies in lung cancer and cardioprotection.
Corporate Developments and Quality Assurance
Beyond clinical progress, Racura has strengthened its operational capabilities with the appointment of Dr Suzanne McCusker as Corporate Operations Manager, enhancing governance and organisational planning. Additionally, senior executives conducted supplier audits in China, underscoring the company’s commitment to quality assurance and regulatory compliance.
Post-quarter, the Bellberry Human Research Ethics Committee approved expansion of the HARNESS-1 trial to additional Australian sites, including Chris O’Brien Lifehouse and Austin Health, which will support increased patient recruitment and trial momentum.
Shareholder Base and Market Position
Racura’s shareholder count grew during the quarter, with more investors holding meaningful stakes above 5,000 shares. CEO Dr Daniel Tillett remains a significant shareholder with a 10.29% holding, aligning management and investor interests as the company progresses its oncology pipeline.
With multiple clinical programs targeting high-value MYC-driven cancers and a well-funded balance sheet, Racura is positioned to deliver on key milestones that could unlock further value for patients and shareholders alike.
Bottom Line?
Racura’s clinical and financial momentum sets the stage for upcoming trial readouts and potential partnership opportunities, but investors should watch for early-phase trial data and regulatory developments.
Questions in the middle?
- How will the safety and efficacy data from the HARNESS-1 trial influence RC220’s clinical trajectory?
- What are the timelines and potential catalysts for the Phase 3 EMILI trial in AML?
- Could Racura secure strategic partnerships to accelerate global commercialisation of RC220?